Development and multicenter validation of an LC-MS-based bioanalytical method for antisense therapeutics

Bioanalysis. 2022 Sep;14(18):1213-1227. doi: 10.4155/bio-2022-0126. Epub 2022 Nov 21.

Abstract

Background: Many bioanalytical methods for antisense oligonucleotides (ASOs) using LC-MS have been reported. However, no data have been available on the reproducibility and robustness of a single bioanalytical method for ASOs. As such, in the current study, we evaluated the reproducibility and robustness of LC-MS-based bioanalytical methods for ASOs in multiple laboratories. Methods/Results: Seven independent laboratories were included in this study. Mipomersen was measured by ion-pairing LC-MS (IP-LC-MS) as a model ASO using different LC-MS. The validation results of calibration curve, accuracy, precision and selectivity met the criteria of conventional bioanalytical method validation guidelines using LC/GC-MS for drugs in all laboratories. Meanwhile, carryover (>20%) was detected in three laboratories. Conclusion: We first demonstrated the multicenter-validated IP-LC-MS bioanalytical method for ASOs. Our data showed that the method was sensitive, robust and reproducible. However, the occurrence of carryover should be carefully monitored in its future application.

Keywords: Clarity OTX; LC–MS bioanalysis; antisense oligonucleotide; ion-pairing reagent; multilaboratory validation.

Publication types

  • Multicenter Study

MeSH terms

  • Biological Therapy*
  • Calibration
  • Chromatography, Liquid / methods
  • Reproducibility of Results
  • Tandem Mass Spectrometry* / methods